Edition:
United Kingdom

Solid Biosciences Inc (SLDB.OQ)

SLDB.OQ on NASDAQ Stock Exchange Global Select Market

27.50USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$27.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$29.25
52-wk Low
$19.12

Summary

Name Age Since Current Position

Andrey Zarur

Chairman of the Board, Co-Founder

Gilad Hayeem

President, Co-Founder, Director

Ilan Ganot

Chief Executive Officer, Co-Founder, Director

Alvaro Amorrortu

Chief Operating Officer

Jorge Quiroz

Chief Medical Officer

Biographies

Name Description

Andrey Zarur

Dr. Andrey J. Zarur, Ph.D. is Chairman of the Board, Co-Founder of the Company. Zarur is Co-Founder of the Comapny. He has been active in early stage life sciences companies for more than 20 years, and has participated in the creation of more than a dozen companies in the healthcare and clean energy sectors. He is also Chairman, CEO and Founder of GreenLight Biosciences and a partner at Kodiak Venture Partners, a venture capital firm specializing in the formation of early stage information and life technology investments. Prior to joining Kodiak Venture Partners, he was founder and CEO of BioProcessors, which was sold to Seahorse Biosciences in 2007. In addition to BioProcessors, he has led four life science companies from inception to exit. Dr. Zarur is also a co-founder and chairman of the board for Lumicell, and chairman of the board for Allegro Diagnostics. Dr. Zarur was named a Young Global Leader of the World Economic Forum in 2005. He is an Overseer of the Museum of Science in Boston and a Senior Lecturer at the Massachusetts Institute of Technology (MIT) Sloan School of Management. Dr. Zarur holds Masters of Science degrees and a Ph.D. in Chemical Engineering from MIT and undergraduate degrees from the National University of Mexico. Dr. Zarur is the author of several peer-reviewed articles and holds close to 100 provisional and issued patents.

Gilad Hayeem

Mr. Gilad D. Hayeem is President, Co-Founder, Director of the Company. Hayeem founded Solid Biosciences through his Family Office, Waverly Capital, and led the Series A round alongside JPMorgan. Mr. Hayeem was Managing Partner and CEO of Marble Bar Asset Management, a UK based investment fund he founded in 2002, which he exited in 2010. Mr. Hayeem then moved to New York where he lives with his wife and four children. Mr. Hayeem received his MBA from City University, London and holds history and politics degrees from the University of Leeds, England.

Ilan Ganot

Mr. Ilan Ganot is Chief Executive Officer, Co-Founder, Director of the Company. He started Solid in 2013 to find treatments, and potentially a cure, for Duchenne muscular dystrophy, a disease that afflicts his son Eytani. Prior to starting Solid, Mr. Ganot was an investment banker at JPMorgan Chase in London, specializing in hedge fund driven equities business for the firm. Mr. Ganot also worked at Nomura Securities in London, Hong Kong and New York, where he managed relationships with investors and clients of the firm. Prior to Nomura, Mr. Ganot was a senior salesperson for Lehman Brothers’ European Equities business. Mr. Ganot embarked on a banking career after practicing law at the Israeli law-firm, Haim Zadok & Co, where his focus was private equity law and mergers and acquisitions. Prior to practicing law, Mr. Ganot was division head at Vir-Tech, a laser engraving business, and a captain in the Israel Defense Forces. Mr. Ganot received his MBA from London Business school and holds law and business degrees from the IDC in Herzliya, Israel.

Alvaro Amorrortu

Mr. Alvaro Amorrortu is Chief Operating Officer of the Company. Prior to joining Solid Biosciences, Mr. Amorrortu spent more than a decade as a management consultant advising biopharmaceutical companies on a variety of strategic challenges, including overseeing large scale organizational transformations as well as designing strategies for assets and portfolios moving from early stages of development to commercial launch. His career as a strategist started at the Monitor Group, and then after a few years working for Inventiv Health (Campbell Alliance), moved to IMS Health. In addition, Mr. Amorrortu brings to Solid Biosciences, hands on experience managing operations. He held leadership positions in Bunge Group and Cargill subsidiaries, where he was responsible for running manufacturing facilities as well as complex engineering projects. Mr. Amorrortu received his M.B.A. with a major in Finance from The Wharton School and graduated from the Instituto Tecnologico de Buenos Aires, Argentina with an MS in Industrial Engineering.

Jorge Quiroz

Mr. Jorge A. Quiroz, M.D. is Chief Medical Officer of the Company. He provides leadership and clinical vision for the company, as well as being responsible for the clinical programs in patients with DMD. Prior to joining Solid, Dr. Quiroz served as the Head of Neurodevelopment & Psychiatry, Translational Medicine Neurosciences at Hoffmann-La Roche. A medical graduate from the Pontifical Catholic University of Chile and Board Certified Psychiatrist, he completed his medical training as a Research Fellow at the Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, at the National Institutes of Health in Bethesda, Maryland. He also holds a Master of Business Administration dual degree from Columbia University & London Business School. Dr. Quiroz received the NARSAD Young Investigator Award, the NCDEU New Investigator Award, the Fellows Award for Research Excellence, and the NIH Clinical Center Director’s Award, among other distinctions. He has designed and conducted numerous proof of concept studies, including studies in orphan designated indications, and has successfully filed New Drug Applications with the FDA during his tenure at Johnson & Johnson Pharmaceutical Research and Development and Hoffmann-La Roche. Dr. Quiroz has published over 45 peer reviewed scientific publications and book chapters in the fields of translational neurosciences and drug development.

Basic Compensation

Options Compensation